Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Captor TherapeuticsWAR:CTX -2.52%38 PB Ratio is 33.73 as of Jul. 14, 2026, which is 439% above its 10-year median of 6.26. GuruFocus rates WAR:CTX with a GF Score™ of 38/100 and a GF Value™ of zł10.13 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,228 Biotechnology companies, Captor Therapeutics ranks worse than 95.85% on this metric.
Captor Therapeutics SA stock PB Ratio (=34.6) is close to 10-year high of 37.59.
The historical rank and industry rank for Captor Therapeutics's PB Ratio or its related term are showing as below:
WAR:CTX'
s PB Ratio Range Over the Past 10 Years
Min: 3.21 Med: 6.26 Max: 37.59
Current: 33.73
During the past 9 years, Captor Therapeutics's highest PB Ratio was 37.59. The lowest was 3.21. And the median was 6.26.
WAR:CTX's PB Ratio is ranked worse than 95.85% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs WAR:CTX: 33.73
During the past 12 months, Captor Therapeutics's average Book Value Per Share Growth Rate was -77.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.10% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Captor Therapeutics was 205.60% per year. The lowest was -43.10% per year. And the median was 66.60% per year.
Back to Basics: PB Ratio
Captor Therapeutics (WAR:CTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Captor Therapeutics PB Ratio Related Terms
Captor Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Captor Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Captor Therapeutics (WAR:CTX) has a PB Ratio of 33.73 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Captor Therapeutics and its competitors. This is 439% above median its historical median of 6.26. Over the past decade, Captor Therapeutics' PB Ratio has ranged from 3.21 to 37.59. According to the industry distribution chart, Captor Therapeutics ranks #1177 out of 1228 companies in the Biotechnology industry, placing it in the top 95.8%.
Is Captor Therapeutics' PB Ratio too high?
Captor Therapeutics' current PB Ratio of 33.73 is 439% above median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 37.59. The Biotechnology industry median PB Ratio is 2.89. Captor Therapeutics' value of 33.73 is 1069.2% above this industry median. Based on the distribution chart, Captor Therapeutics ranks #1177 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #1177 out of 1228 companies for PB Ratio. This places Captor Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.89. Captor Therapeutics' value of 33.73 is 1069.2% above this benchmark. Historically, Captor Therapeutics' own PB Ratio has ranged from 3.21 to 37.59 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 2.89, Captor Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Captor Therapeutics's current PB Ratio of 33.73 is 1069.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Captor Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Captor Therapeutics's current PB Ratio is 33.73, which is 439% above median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current PB Ratio is 33.73, which is 439% above median its 10-year median of 6.26 and 1069.2% above the Biotechnology industry median of 2.89. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current PB Ratio is 33.73 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
PB Ratio: 33.73 (439% above median its 10-year median of 6.26)
GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
Industry Position: 1069.2% above the Biotechnology median (#1177 of 1228)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score
Get the complete analysis for WAR:CTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
